TRANSCODE THERAPEUTICS, INC.

Transforming the diagnosis and treatment of cancer

TransCode Therapeutics, Inc. is focused on the discovery, development and commercialization of a pipeline of innovative diagnostics and therapeutics for the detection and treatment of cancer, with an initial focus on metastasis. TransCode’s vision is to be the leader in Personalized Cancer Treatment employing data-driven cancer diagnostics as well as optimized targeted treatment solutions for each individual cancer patient that results in a significant improvement in their outcome.

Individualized Patient Approach

Strategic Drivers

Significantly Improve Cancer Outcomes - Focus on Metastasis
Data Driven - Translational Bioinformatics
Early Diagnostic Detection of Disease
Targeted Cancer Therapeutics

Conventional therapies aimed at treating primary cancer oftentimes are ineffective at treating metastatic cancer, resulting in poor outcomes in patients diagnosed with metastatic disease.

Improve Cancer Outcomes

Metastatic tumor cells are anatomically, biologically, and physiologically distinct from primary tumor cells
A need for differential treatment is paramount
Primary goal is to significantly improve treatment outcomes in patients with late stage disease
Combine data driven diagnostics with personalized treatment solutions to provide lasting regression of metastatic disease without recurrence
Treat individual patients based on mutation type, stage of disease and biomarker expression
Optimize dose and treatment duration for each individual patient

Data Driven

Identify key biomarkers associated with primary and metastatic cancers
Apply highly specific biomarker diagnostic tools for cancer detection and staging
Assimilate biomarker expression data, stage of disease, tumor type, aggressiveness of disease etc.
Translational bioinformatics - data to inform therapeutic decision making and early intervention

Early Detection

The staple of reducing mortality due to cancer has been early detection.

Utilize novel diagnostic biomarkers for the presence of metastasis
Develop predictive biomarkers for early diagnosis of metastasis and disease progression
Identify patients at increased risk of progression
Stratify tumors based on aggressiveness to better inform treatment

Targeted Therapies

Therapeutic pipeline targeting metastasis
Treatment with lead-candidate therapeutic leads to durable regression/elimination of established metastases in murine models of metastatic breast cancer
Broad applicability across multiple tumor types
Image-guided treatment combines knowledge of drug bioavailability & outcome
Delivery-based therapeutic platform - backbone of therapeutic pipeline
Therapeutics targeting specific biomarkers in multiple cancer types
Combination therapies as a multipronged approach to treatment